

## PERMISSION TO USE

In presenting this dissertation in partial fulfillment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis/dissertation in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my dissertation work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this dissertation or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my dissertation.

Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to:

Head of Department of Veterinary Biomedical Sciences  
University of Saskatchewan  
Saskatoon, Saskatchewan S7N 5B4

## PREFACE

This dissertation has been organized as a series of manuscripts which were or will be submitted for publication to peer-reviewed scientific journals. Thus, some repetition of introductory or methodology material is unavoidable.

## ABSTRACT

*Lawsonia intracellularis* causes proliferative enteropathies in juvenile mammals. The porcine (PPE) and equine (EPE) diseases are worldwide. Rabbits and hamsters are naturally susceptible, the latter being a classic modeling-host for PPE. None is known for EPE, besides foals. An *in vitro* evaluation of antimicrobial efficacy against *L. intracellularis* is difficult. This study aimed to validate a laboratory animal EPE model and to investigate pharmacokinetics (PK) and efficacy of gallium maltolate (GaM) as an alternative antimicrobial therapy. Infected animals were inoculated with cell-cultured *L. intracellularis* and infection was verified with clinically utilized diagnostic tests.

Initially, 2 groups of EPE-infected rabbits were compared to 1 uninfected group. After inoculation (PI), EPE-infected rabbits showed mild clinical signs; detectable seroconversion, fecal shedding, gross lesions in intestinal tissues (IT), and early immuno-histochemistry labeling of *L. intracellularis* antigen. Thus, a humane EPE-rabbit model was achieved. Subsequently, EPE-infected hamsters were compared to uninfected and PPE-infected hamsters; whereas, PPE-infected rabbits were compared to EPE-infected rabbits. EPE-hamsters did not develop infection, unlike PPE-infected controls; and PPE-rabbits did not develop IT lesions or seroconversion comparable to EPE-rabbits.

Therefore rabbits were chosen as the EPE modeling-host for the GaM studies. First, GaM PK and IT concentrations of Ga and Fe were measured. Then, GaM efficacy was compared to a current EPE antimicrobial treatment. During sampling, the intra-arterial catheters in the rabbits' ears were protected with a novel moleskin-cover, allowing repeated sampling while minimally restrained.

The PK study was based on the comparison of EPE-infected and uninfected rabbits, after a single treatment with GaM, collection of serial blood samples and IT samples. The only differing PK parameter, between groups, was a decrease in the terminal phase rate constant of the EPE-rabbits, so a 48h dosing interval was chosen for the efficacy study.

In the efficacy study, 3 groups of EPE-infected rabbits were treated with GaM, doxycycline and a placebo, respectively. No differences were noted between treatments, in terms of lesions and fecal shedding. GaM appears no more efficacious than doxycycline in EPE-rabbits. In conclusion, albeit GaM tolerance appeared adequate in rabbits, results do not support its use in EPE-infected animals.

## ACKNOWLEDGEMENTS

I would like to express my heartfelt gratitude to my supervisor Dr. Don L. Hamilton for his support through every step of my growth, as a laboratory researcher, critical thinker, statistician and better writer. To Dr. Julie Thompson I extend my thanks for having introduced and guided me to the unknown world of Synchrotron Radiation Analysis, trying to merge high-end technology and inorganic science with biomedical disciplines. To Drs. Chris R. Clark and Trisha M. Dowling, go my deep respect and gratitude for having introduced me to a different approach to pharmacology, teaching and antimicrobial drugs in veterinary medicine. My most sincere thanks go also to Dr. Jane Alcorn, as her help and dedication have been fundamental in transforming an equine medicine clinician into a researcher with a passion for laboratory animal models and pharmacokinetics. Last but not least, a special thanks to Dr. Gillian Muir for her supportive encouragement and a well thought-out opinion always available. As there are just so many ways in English to say “thanks” for their time, their help and for having put up with the turns my life has taken during my doctoral studies, I’m happy to say that I will never forget their commitment and example. I hope one day, as a sign of thanks to them, I will be able to pass on the grace they bestowed upon me to the people I will train and guide in scientific research.

The accomplishment of this dissertation includes people that were not directly involved in my advisory committee, but due to their dedication, constant presence and support they felt like they were. Thus, my gratitude goes to Dr. Andrew Allen (University of Saskatchewan, Saskatoon, SK), who guided me through those pathology branches that I’ve never appreciated so deeply, as a clinician, as I do now; To Drs. Connie Gebhart and Fabio Vannucci (University of Minnesota, St. Paul, MN, USA) who taught me about *Lawsonia intracellularis* and its genetics, the immunohistochemistry, serology techniques, cell cultures and infection model challenges, more than I ever imagined; To Drs. Nicola Pusterla and Samantha Mapes (University of California Davis, Davis, CA, USA) I express my gratitude for their precious contribution of extensive qPCR analysis and neverending support in “our bunny” research.

Special thanks go to my family and to those friends without whom it would have never been possible to drive this project to completion, much like thanking fellow riders through an endurance ride: Drs. Katherine R. Ball, DVM, Rekha T. Orchard, DVM, Joseph Rubin, DVM, Kim A. Tryon, DVM, Kelly M.N. MacLellan, DVM, Jasmine M Dhillon, DVM, Sheryl Gow,

DVM, Murray Jelinski, DVM and finally my husband COL. Kevin C. Smith, DO. A very special “thank you” goes to a veterinary student, Aphroditi J. Antonopoulos, who has been an incredible asset to my research: her presence and enthusiasm made everyone’s day better (including the animals’). Thanks to their support and knowledge, most conversations became learning experiences and many complicated steps of the research were simplified, or at least eased.

I would like to express my gratitude to Dr. Colette Wheler (University of Saskatchewan, Saskatoon, SK) for training me for appropriate laboratory animals handling and always being open to lend instruments or advice; Dr. Ernest Olfert for helping with experienced advice about pertinent literature on rabbit models and rabbit catheterization. At this stage, it is fundamental to thank the Animal Care Unit personnel that helped during experiment time: Ms. Monique Burmester, Mrs. Paula Mason, Mel Browning and E.D. Parsons. Without their expertise and encouragement, the project would have been a daunting challenge. Equally my thanks go to Mrs. Cathy Coghlin, Darlene Hall, Cheryl Hack and Sandra Rose for their precious help in shipping samples to Minnesota or California: thanks to their professionalism and organization every sample collected arrived at destination in due time.

Also, for the submission of the 5 data chapters as articles in peer-reviewed journals I would like to acknowledge Ms. A.T. Gebhart, for the attentive editing provided and the many suggestions.

These studies were funded by a grant from the 2009 Equine Health Research Fund of the Western College of Veterinary Medicine and (in part) by a 2008 NSERC Grant (“Synchrotron microanalysis of gallium as a potential therapy for antimicrobial-resistant urinary tract infections”). As a Fellow Trainee I think it is my duty to acknowledge the CIHR-THRUST (Canadian Institutes of Health Research - Training Grant in Health Research Using Synchrotron Techniques) and all the supporters within the Synchrotron community at the Canadian Light Source, particularly Drs. Robert Blyth, Lucia Zuin and Renfei Feng.

Finally I would like to acknowledge the animals (hamsters and rabbits) that were used for these experiments, hoping that our experimental results will encourage other researchers, near and far, to be respectful of what animal models can provide and teach.

## DEDICATION

This dissertation is dedicated to several people in my life, as their constant presence made it possible for me to achieve such a prestigious goal with passion and determination.

To my husband, Kevin, as he kindly supported me through every step of this adventure with patience, encouragement and love.

To my parents, Giuseppe and Rita, as their encouragement and unconditional love never faltered through a far distance and... the third thesis;

To my in-laws, Charles and Norma, as their support and understanding came unconditioned and total from the day I've met them;

To my Alabamian family, Jeanne, Jerry, Peggy and Bob, for they supported me as their own daughter and niece with love and advices.

To my brother and sister, Raffaele and Cristiana, and to the brothers and sisters of my heart, Chris and Kim, Sam, Tommy and Nichole, Wes and Sandra, Rita and Kim, Mala, and Lucia, as they always pushed me with a smile to never give up, even when things were difficult.

Last but not least, this dissertation is dedicated to my yet unborn son, to show him that commitment runs in the family and I'll be committed to him the same way I'm committed to good science. All my life.

## TABLE OF CONTENTS

PERMISSION TO USE .....	i
PREFACE .....	ii
ABSTRACT.....	iii
ACKNOWLEDGEMENTS .....	iv
DEDICATION.....	vi
TABLE OF CONTENTS .....	vii
LIST OF TABLES.....	xi
LIST OF FIGURES.....	xii
LIST OF ABBREVIATIONS.....	xv
<b>CHAPTER 1. INTRODUCTION.....</b>	<b>1</b>
<b>CHAPTER 2. LITERATURE REVIEW.....</b>	<b>3</b>
2.1. Equine Proliferative Enteropathy: <i>Lawsonia intracellularis</i> infection in horses and present knowledge of the disease.....	3
2.1.1. Gastro-enteric diseases in foals.....	3
2.1.2. Equine proliferative enteropathy: from sporadic beginnings to outbreaks.....	6
2.1.3. Epidemiology and clinical appearance of EPE.....	10
2.1.4. Pathogenesis of EPE.....	12
2.2. <i>Lawsonia intracellularis</i> : the challenges of its discovery.....	17
2.2.1. The challenges of a timely-fashioned clinical diagnosis: past and present techniques.....	19
2.2.2. Serology.....	20
2.2.3. Fecal smears analysis: from immunology tests to PCR analysis.....	25
2.2.4. Immunohistochemistry: achieving the gold standard.....	30
2.3. Current therapeutic approaches and EPE management in horses.....	32
2.3.1. Current antimicrobial therapy in EPE affected foals.....	33
2.3.2. Experimental background to the clinical therapy.....	35
2.3.3. Current use of immunization.....	39
2.4. Pharmacokinetics and pharmacodynamics of AM drugs potentially useful against EPE.....	43
2.4.1. Pharmacokinetic considerations.....	43
2.4.2. Pharmacodynamic considerations.....	48
2.4.3. An alternative antimicrobial prospect: Gallium maltolate.....	50
2.5 Gastrointestinal function.....	56
2.5.1 Physiology of intestinal absorption.....	57
2.5.2. Pathogenesis of malabsorption .....	63
2.5.3. Tests to evaluate intestinal integrity and absorption ability .....	63
2.5.4. Iron absorption .....	66
2.6 Animal models.....	70
2.6.1. The beginnings of the research on animal models.....	74

2.6.2. Rabbits and hamsters as animal models .....	76
2.6.3. Animal models for <i>Lawsonia intracellularis</i> .....	80
<b>CHAPTER 3. OBJECTIVE AND HYPOTHESIS .....</b>	<b>83</b>
<b>CHAPTER 4. THE RABBIT AS AN INFECTION MODEL FOR EQUINE PROLIFERATIVE ENTEROPATHY.....</b>	<b>86</b>
4.1. Abstract.....	87
4.2. Introduction.....	87
4.3. Materials and Methods.....	89
4.3.1. Animals.....	89
4.3.2. Inoculum preparation.....	90
4.3.3. Inoculation procedure.....	91
4.3.4. Collection of samples.....	91
4.3.5. Sample analysis.....	92
4.3.6. Statistics.....	96
4.4. Results.....	96
4.4.1. Clinical findings.....	96
4.4.2. Necropsy findings.....	99
4.4.3. Histology and Immunohistochemistry.....	102
4.4.4. Serum Analyses.....	106
4.4.5. Quantitative PCR.....	108
4.5. Discussion.....	110
<b>CHAPTER 5. SPECIES-SPECIFICITY OF EQUINE AND PORCINE <i>L.</i> <i>INTRACELLULARIS</i> ISOLATES IN LABORATORY ANIMALS.....</b>	<b>114</b>
5.1. Abstract.....	115
5.2. Introduction.....	115
5.3. Materials and Methods.....	117
5.3.1. Animals: Hamsters.....	118
5.3.2. Animals: Rabbits.....	119
5.3.3. Inoculum preparation.....	120
5.3.4. Inoculation procedures.....	121
5.3.5. Collection of samples.....	122
5.3.6. Sample analysis.....	126
5.3.7. Statistics.....	128
5.4. Results.....	128
5.4.1. Clinical appearance.....	128
5.4.2. Gross pathology.....	131
5.4.3. Immunohistochemistry.....	133
5.4.4. Serology.....	140
5.4.5. Quantitative PCR.....	142
5.5. Discussion.....	148
<b>CHAPTER 6. PROTECTING SHORT-TERM EAR CATHETERS IN HEALTHY</b>	



<b>RABBITS</b> .....	<b>152</b>
6.1. Abstract.....	153
6.2. Introduction.....	153
6.3. Materials and Methods.....	155
6.3.1. Animals.....	155
6.3.2. Ear Preparation.....	155
6.3.3. Preparation of supplies.....	157
6.3.4. Placement of the catheter and protection cover.....	159
6.3.5. Maintenance of the Catheter: repeated sampling.....	167
6.3.6. Removal of the catheter and recovery of the ar.....	169
6.4. Results.....	173
6.5. Discussion.....	178
<b>CHAPTER 7. PHARMACOKINETICS OF GALLIUM MALTOLATE IN LAWSONIA INTRACELLULARIS-INFECTED AND UNINFECTED RABBITS</b> ....	<b>180</b>
7.1. Abstract.....	181
7.2. Introduction.....	181
7.3. Materials and Methods.....	184
7.3.1. Animals.....	184
7.3.2. <i>L. intracellularis</i> rabbit infection model.....	184
7.3.3. Study design.....	185
7.3.4. Sample collection.....	186
7.3.5. Verification of infection.....	187
7.3.6. Elemental Iron and Gallium tissue concentration.....	187
7.3.7. Pharmacokinetic analysis.....	188
7.3.8. Statistics.....	188
7.4. Results.....	189
7.4.1. Clinical appearance.....	189
7.4.2. Pharmacokinetics.....	192
7.4.3. Gross pathology.....	197
7.4.4. Intestinal tissue Fe(III) and Ga(III) concentrations.....	197
7.4.5. Serology.....	203
7.4.6. Histology and immunohistochemistry.....	203
7.4.7. PCR.....	203
7.5. Discussion.....	206
<b>CHAPTER 8. EFFICACY OF GALLIUM MALTOLATE AGAINST LAWSONIA INTRACELLULARIS INFECTION IN A RABBIT MODEL</b> .....	<b>210</b>
8.1. Abstract.....	211
8.2. Introduction.....	211
8.3. Materials and Methods.....	214
8.3.1. Animals.....	214
8.3.2. <i>L. intracellularis</i> rabbit infection model.....	214
8.3.3. Study design.....	215
8.3.4. Sample collection.....	215

8.3.5. Verification of infection.....	216
8.3.6. Statistics.....	217
8.4. Results.....	217
8.4.1. Clinical appearance.....	217
8.4.2. Gross pathology.....	219
8.4.3 Serology .....	219
8.4.4. Histology and immunohistochemistry.....	219
8.4.5. PCR.....	219
8.4.6. Gallium and Iron elemental analysis.....	225
8.5. Discussion.....	228
<b>CHAPTER 9. GENERAL DISCUSSION.....</b>	<b>233</b>
9.1. Animal Modeling Phase.....	233
9.1.1. Rabbit model.....	233
9.1.2. Hamster model.....	234
9.1.3. Considerations and Discussion.....	235
9.2. Pharmacology phase.....	239
9.2.1. Ear Catheterization and Timely Sample Collection.....	239
9.2.2. Pharmacokinetics (PK) Study.....	239
9.2.3. Synchrotron Radiation Analysis.....	240
9.2.4. Efficacy study.....	240
9.2.5. Considerations and Discussion.....	241
<b>CHAPTER 10. CONCLUSIONS.....</b>	<b>242</b>
<b>CHAPTER 11. BIBLIOGRAPHIC REFERENCES.....</b>	<b>245</b>
<b>APPENDIX A.....</b>	<b>283</b>

## LIST OF TABLES

<b>Table 2.1.</b>	Serological techniques used for diagnosis of proliferative enteropathy exposure in porcine (PPE), equine (EPE), and lapine species (rabbits).....	22
<b>Table 2.2.</b>	Diagnostic techniques utilized to detect <i>L. intracellularis</i> in fecal or tissue samples in the porcine (PPE), equine (EPE), or other species.....	26
<b>Table 4.1.</b>	PCR analysis details. Specific forward and reverse primers sequences, along with probe, target gene and accession numbers for the technique of PCR utilized in the diagnosis of <i>L. intracellularis</i> fecal shedding.....	95
<b>Table 4.2.</b>	Immunohistochemistry (IHC) results in <i>L. intracellularis</i> orally inoculated rabbits.....	103
<b>Table 5.1.</b>	Humane Intervention Monitoring Parameters for the hamster studies.....	123
<b>Table 5.2.</b>	Humane Intervention Monitoring Parameters for the rabbit studies.....	125
<b>Table 7.1.</b>	Pharmacokinetic parameter estimates for healthy uninfected rabbits after a single oral bolus of gallium maltolate (50 mg/kg BW).....	195
<b>Table 7.2.</b>	Pharmacokinetic parameter estimates for 6 EPE-infected rabbits after a single oral bolus dose of gallium maltolate (50 mg/kg BW).....	196

## LIST OF FIGURES

<b>Figure 2.1.</b>	Gallium maltolate chemical structure.....	53
<b>Figure 4.1.</b>	Body weight (kg) changes in rabbits infected with <i>L. intracellularis</i> .....	98
<b>Figure 4.2.</b>	<b>(4.2.1 to 4.2.4)</b> Comparisons of infected and uninfected jejunum in a rabbit model for <i>L. intracellularis</i> infection.....	101-102
<b>Figure 4.3.</b>	<b>(4.3.1. to 4.3.2.)</b> Immunochemistry stains of infected rabbit intestine...	105
<b>Figure 4.4.</b>	Serologic response detected in experimentally infected and uninfected control rabbits after oral challenge with an equine strain of <i>Lawsonia intracellularis</i> .....	107
<b>Figure 4.5.</b>	Quantitative PCR results in rabbits experimentally infected with equine strain of <i>Lawsonia intracellularis</i> and in uninfected controls.....	109
<b>Figure 5.1.</b>	Comparison of body weight changes in infected rabbits.....	130
<b>Figure 5.2.</b>	Infected rabbit jejunum. Example of the macroscopic appearance of a tract of jejunum.....	132
<b>Figure 5.3.</b>	<b>(5.3.1. to 5.3.2.)</b> Immunohistochemistry (IHC) results in hamsters. Comparison of IHC labelling in the EPE-strain and the PPE-strain infected hamsters.....	134-135
<b>Figure 5.4.</b>	Comparison between strains infection in hamsters.....	136
<b>Figure 5.5.</b>	<b>(5.5.1. to 5.5.2)</b> Comparison of IHC labelling in EPE- and PPE-infected rabbits.....	138-139
<b>Figure 5.6.</b>	Serology results. Immuno-peroxidase monolayer assay (IPMA) findings indicating antibody response in EPE-strain and PPE-strain infected rabbits.....	141
<b>Figure 5.7.</b>	<b>(5.7.1. to 5.7.3.)</b> Detection of <i>L. intracellularis</i> DNA gene copies ( <i>aspA</i> gene) through qPCR analysis in feces of experimentally infected weanling hamsters.....	143-145
<b>Figure 5.8.</b>	qPCR results in rabbits. Comparison of <i>L. intracellularis aspA</i> gene copies/g of feces obtained through qPCR between EPE-infected versus PPE-infected rabbits.....	147
<b>Figure 6.1.1.</b>	Ear preparation.....	156
<b>Figure 6.1.2.</b>	Preparation of the moleskin: Step 1.....	158

<b>Figure 6.1.3.</b>	Preparation of the moleskin: Step 2.....	158
<b>Figure 6.2.1.</b>	Catheter insertion: Step 1.....	160
<b>Figure 6.2.2. and 6.2.3.</b>	Catheter insertion: steps 2 and 3.....	161
<b>Figure 6.2.4. and 6.2.5.</b>	Catheter insertion: Steps 4 and 5.....	162
<b>Figure 6.2.6.</b>	Catheter insertion: Step 6.....	163
<b>Figure 6.3.1.</b>	Securing the catheter and the moleskin: Step 1.....	164
<b>Figure 6.3.2.</b>	Securing the moleskin: Step 2.....	164
<b>Figure 6.3.3.</b>	Moleskin in place.....	165
<b>Figure 6.4.</b>	Troubleshooting.....	166
<b>Figure 6.5.</b>	Catheter Flush. Flushing of the catheter, which is completely embedded under the moleskin.....	168
<b>Figure 6.6.1.</b>	Removal of the moleskin: Step 1.....	170
<b>Figure 6.6.2.</b>	Removal of the moleskin: Step 2.....	170
<b>Figure 6.6.3.</b>	Removal of the moleskin: Step 3.....	171
<b>Figure 6.7.1.</b>	Appearance of the catheterized ear after removal of the catheter.....	172
<b>Figure 6.7.2.</b>	Aftercare of the rabbit's ear, after the ear has been cleaned and dried...	172
<b>Figure 6.8.</b>	Rabbits with catheter and moleskin protection cover. They are released with their peers in their pen.....	174
<b>Figure 6.9.1.</b>	Ear's recovery 3 days after the catheter and the moleskin protective cover was removed.....	176
<b>Figure 6.9.2.</b>	Ear's recovery 3 days after catheter removal. Another ear's recovery 3 days after the catheter and moleskin were removed.....	176
<b>Figure 6.10.</b>	Ear's recovery 7 days after the catheter and moleskin were removed...	177
<b>Figure 7.1.1.</b>	Body weight changes in uninfected rabbits administered gallium maltolate.....	190
<b>Figure 7.1.2.</b>	Body weight changes in infected rabbits administered gallium	

	maltolate.....	191
<b>Figure 7.2.1.</b>	Concentration versus time curves for uninfected rabbits administered gallium maltolate.....	193
<b>Figure 7.2.2.</b>	Concentration versus time curves for the infected rabbits administered gallium maltolate.....	194
<b>Figure 7.3.1.</b>	Comparison of elemental gallium concentration in EPE-infected rabbits and uninfected controls at 24 h PT.....	199
<b>Figure 7.3.2.</b>	Comparison of elemental iron concentration in EPE-infected rabbits and uninfected controls at 24 h PT.....	200
<b>Figure 7.4.1.</b>	Comparison of elemental gallium concentration in EPE-infected rabbits and uninfected controls at 9 days PT.....	201
<b>Figure 7.4.2.</b>	Comparison of elemental iron concentration in EPE-infected rabbits and uninfected controls at 9 days PT.....	202
<b>Figure 7.5.1.</b>	PCR results before and after gallium maltolate treatment in EPE-infected rabbits.....	204
<b>Figure 7.5.2</b>	PCR results indicating fecal shedding after EPE infection in rabbits: time of onset and subjects variability.....	205
<b>Figure 8.1.1.</b>	Body weight changes in EPE infected rabbits undergoing 3 different AM treatments.....	218
<b>Figure 8.1.2.</b>	Daily variation in body weight in 3 groups of EPE-infected rabbits undergoing 3 different AM treatments.....	219
<b>Figure 8.2.</b>	Daily progression of fecal shedding in EPE-infected rabbits undergoing 3 different AM treatments.....	222
<b>Figure 8.3.</b>	Comparison of <i>L. intracellularis</i> fecal shedding between groups (averaged values).....	223
<b>Figure 8.4.</b>	Comparison of <i>L. intracellularis</i> caecal content between groups (averaged values on day of euthanasia).....	224
<b>Figure 8.5.1.</b>	Accumulation of elemental gallium (in ppb = ng/g) in intestinal tract's sections of EPE-infected rabbits.....	226
<b>Figure 8.5.2.</b>	Concentration of elemental iron (in ppm = µg/g) in intestinal tract's sections of EPE-infected rabbits.....	227

## LIST OF ABBREVIATIONS

AFMA	Americans for Medical Advancement
AM(s)	Antimicrobial(s)
AUC	Area under the curve
Cl <sub>o</sub>	Oral clearance
C <sub>max</sub>	Maximum concentration obtained in serum after drug exposure
DMT-1	Divalent metal transporter-1
DPI or PI	Days after inoculation or Post infection
ELISA	Enzyme Linked Immuno-sorbent Assay
EPE	Equine proliferative enteropathy
Fe(II)	Ferrous Iron
Fe(III)	Ferric Iron
[Fe]	Iron concentration
FISH	Fluorescent in-situ hybridization
[Ga]	Gallium concentration
Ga(III)	Elemental Gallium
GaM	Gallium maltolate
GIT	Gastrointestinal tract
H&E	Haematoxylin and Eosin staining
IFAT	Indirect Fluorescent Antibody Test
IHC	Immunohistochemistry
IPMA	Immunoperoxidase monolayer assay
IPX	Immunoperoxidase
IRE	Iron responsive elements
IRP	Iron regulatory protein (1, 2,...)
ISH	In-situ hybridization
IT	Intestinal tissues
K <sub>m</sub>	Michaelis-Menten affinity constant
mM	Millimole
MRT	Mean residence time
OGAT	Oral glucose absorption test
PCR	Polymerase chain reaction
PE	Proliferative enteropathy (in general, for every species)
PHE	Porcine hemorrhagic enteritis
PIA	Porcine intestinal adenomatosis
PK	Pharmacokinetics
PPE	Porcine proliferative enteropathy
PT	Post treatment
qPCR	Quantitative PCR

$t_{1/2}$	Half-life
$T_{\max}$	Time to reach maximum concentration after drug exposure
$V_{\max}$	Maximum initial rate of an enzyme (in this case) catalysed reaction
VESPERS	Very Sensitive Elemental and Structural Probe Employing Radiation from a Synchrotron
vs.	versus
WS	Warthin-Starry staining
$\lambda$	Elimination rate constant (non-compartmental analysis)
$\mu\text{M}$	micromole